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patient-reported HRQoL. METHODS: We compared baseline
Short Form (SF)-36 scores for individuals with ITP who enrolled
in one of two double-blind, randomized clinical trials for the
treatment of ITP [one group was refractory to splenectomy
(n = 58) and the other had no splenectomy (n = 60)] to general
populations in Canada (n = 9408) and the US (n = 2474). We
also compared ITP-speciﬁc HRQoL burden using the ITP-Patient
Assessment Questionnaire (PAQ) across platelet count categories
(<10 ¥ 109/L vs. 10 to 49 ¥ 109/L). ANOVA tests were used to
compare age and sex-adjusted means across samples. RESULTS:
The mean age of the ITP patients was 53.3  16.2 years, and the
majority (64%) was female. SF-36 scores of ITP patients were
signiﬁcantly (p < 0.0001) worse than those from the Canadian
and US general population for each scale and summary score.
The largest differences were found for physical functioning (67.2
vs. 85.8 and 80.8); role functioning-physical (42.3 vs. 82.1 and
77.0); general health (49.4 vs. 77.0 and 69.9); vitality (40.4 vs.
65.8 and 60.0), and role functioning-emotional (60.5 vs. 84.0
and 80.1). In addition to statistical signiﬁcance, these differences
were clinically meaningful. ITP patients with lower platelet
counts also had worse SF-36 and ITP-PAQ scores, particularly
for symptoms (50.8 vs. 67.8; p < 0.001); fear (65.0 vs. 78.9;
p < 0.05), and social activity scales (59.6 vs. 75.5; p < 0.05) of
the ITP-PAQ. CONCLUSION: ITP was found to impact both
physical and psychological aspects of HRQoL.
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OBJECTIVE: Radiation Therapy Oncology Group (RTOG)
study 0215 was a placebo-controlled, double-blind, cross-over
trial of sildenaﬁl given after radiotherapy and neoadjuvant/
concurrent short-term androgen suppression. Sildenaﬁl improved
erectile function amongst participants. We now report on the
study goal to investigate the effect of sildenaﬁl on marital
and sexual adjustment for participants and their partners.
METHODS: RTOG 0215 closed before meeting its desired
accrual goal with enrollment of 111 eligible patients (72
married). Twenty-four patients (mean age: 72.6  6.8 y) and
their married partners (mean marriage duration: 37.2  16.3 y)
completed the self-report assessments of erectile function and of
marital and sexual adjustment using the validated measures of
the Locke’s Marital Adjustment Test (LMAT) and the Sexual
Adjustment Questionnaire (SAQ). Statistical differences in and
correlations between the change in LMAT and SAQ scores were
tested for signiﬁcance from placebo to sildenaﬁl. RESULTS:
There was no signiﬁcant change in LMAT scores for either
patients (p = 0.37) or partners (p = 0.35). The change in patient
SAQ score was statistically signiﬁcant, but not clinically mean-
ingful (D = 2.58, p = 0.02), while partners reported a smaller
change in SAQ score (D = 1.47, p = 0.47). The correlations
between patient and partner LMAT change scores (r = 0.40,
p = 0.09) and SAQ change scores (r = 0.15, p = 0.48) were non-
signiﬁcant. Patient LMAT and SAQ change scores (r = 0.38,
p = 0.08) were not signiﬁcantly correlated. However, the partner
LMAT and SAQ change scores (r = 0.45, p = 0.04) were signiﬁ-
cantly correlated. CONCLUSION: Erectile dysfunction (ED)
affects, and is affected by, the patient, their partner and the
relationship. ED treatment appears to signiﬁcantly inﬂuence
female partner sexual adjustment and marital adjustment. These
results are tentative and should be considered as an exploratory
basis for a larger clinical trial. The small sample size may have
precluded detection of important other endpoints, which should
not be excluded from future investigations.
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OBJECTIVE: To systematically identify utility weights for health
states in breast cancer. METHODS: Searches were performed of
electronic databases (PubMed, EMBASE and the Cochrane
Library, including DARE, NHS EED and HTA databases) and
internet resources for the period 1990 to date. Sources poten-
tially containing relevant information were retrieved and
reviewed. RESULTS: Fifty-nine studies were identiﬁed as poten-
tially containing utility weights for breast cancer health states.
These were assessed for methodological compliance with the
NICE reference case, leading to the exclusion of 50 non-
compliant studies. Within the remaining nine studies there was
wide variability between both alternative NICE compliant esti-
mates for similar health states, and the health states deﬁned. In
some cases estimates for poor health states (for example meta-
static disease) were higher than those for good health states (for
example remission). For some health states (notably terminal
disease) there are no estimates available based on NICE recom-
mendations. CONCLUSION: A review of utility weights for
breast cancer health states has revealed high levels of uncertainty
within the identiﬁed estimates. Despite the quantity of informa-
tion available there is no universally accepted set of health states
covering the whole of the disease pathway for breast cancer,
which has lead to the development of numerous utility estimates
for numerous health states. The review also highlighted that the
majority of studies undertaken (85% of potential studies identi-
ﬁed) do not conform to the methodological standards stipulated
in the NICE reference case. This is predominantly due to the
elicitation method used. For some health states there are no
estimates available based on these recommendations. It is a dif-
ﬁcult task to identify a coherent set of health state utilities cov-
ering the entire disease pathway in breast cancer using previously
published data and which conform to NICE standards.
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OBJECTIVE:Cancer clinical trials frequently incorporate quality
of life (QL) measures, but rarely patient utility and resource
utilization. Cost utility evaluations of novel cancer therapies
remain challenging. Here we explore the correlation between
QL data from the EORTC QLQ-C30 with the EQ5D, for which
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published utility values exist. METHODS: Consecutive outpa-
tients with non-small cell lung cancer (NSCLC) attending a major
Canadian cancer centre completed the EORTC QLQ-C30 and
EQ5D on a single visit. Different patient disease states included:
1) relapse-free post-resection, including on preventive chemo-
therapy; 2) in relapse, including on palliative chemotherapy or
targeted therapy (erlotinib); and 3) on chemoradiation for locally
advanced NSCLC. Exploratory correlation of EORTC QLQ-C30
and EQ-5D scores is ongoing. RESULTS: A total of 172 patients
participated. The median age of the sample was 65, (range 32–85
years); 47% were male. Half had advanced NSCLC (51%), 41%
were relapse-free post-resection, and 8% had locally advanced
NSCLC. Nearly half of relapse-free patients received preventive
chemotherapy. Twenty-seven percent of advanced NSCLC
patients were receiving palliative chemotherapy, 35% targeted
therapy with erlotinib, and the rest were not on active treatment.
Utility values (based on the EQ5D) were not signiﬁcantly different
among groups, including by disease status (relapse-free versus
in relapse), and current treatment (chemotherapy, erlotinib or
observation). Mean utilities were similar for relapse-free patients
despite treatment, 0.76, and minor differences were seen among
those in relapse, (on chemotherapy, mean utility 0.69; on erlotinib
0.77, on supportive care, 0.75). Exploratory correlation of
EORTC QLQ-C30 and EQ5D values will be presented. CON-
CLUSIONS: QL values in the derivation of patient utility for
different health states in clinical trials may further the ability to
estimate cost utility of novel therapies in cancer clinical trials.
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OBJECTIVES: Intravenous bisphosphonate use in cancer
patients is associated with exposed and necrotic jaw bone, called
Osteonecrosis of the Jaw (ONJ). The overall aim of this pilot
study was to develop a survey that captured the oral health-
speciﬁc and the global health related quality of life (HRQoL)
impact of ONJ, to test the feasibility of survey instruments and to
assess subject distress. METHODS: A 30 minute phone survey
was created with multi-disciplinary collaboration. Four stan-
dardized ONJ health states were developed and subjects’ prefer-
ences (utility) for each state were obtained using the Visual
Analogue Scale (VAS), the EQ5D and time-tradeoff (TTO) ques-
tions. A Visual Basic Interface was constructed to guide the
interviewer through TTO questions designed for the survey. The
subject’s life before and after ONJ was evaluated with the Oral
Health Impact Proﬁle (OHIP). Emotional discomfort during and
after survey was evaluated on a ﬁve point Likert scale. Subjects
were randomly identiﬁed from a cohort of 80 cancer patients
with ONJ. RESULTS: The pilot study included ﬁve patients
(response rate = 100%). Utility decreased with increasing ONJ
stage for all HRQoL instruments: 0.76, 0.97, 0.86 (Cancer and
No ONJ), 0.72, 0.88, 0.83 (Cancer and Stage 1 ONJ), 0.43,
0.52, 0.63 (Cancer and Stage 2 ONJ) and 0.34, 0.39, 0.56
(Cancer and Stage 3 ONJ) for VAS, EQ5D and TTO respectively.
With a baseline mean of 1.6, the OHIP score increased to 7.2
after ONJ (0–28 scale). Two subjects ranked 2 (“a little”) for the
level of emotional discomfort during the survey, but none were
upset afterwards. CONCLUSIONS: Based on preliminary
results, the study design was feasible and both oral health-speciﬁc
and global HRQoL instruments were sensitive to QoL changes
associated with ONJ. All HRQoL instrument performance
showed appropriate rank ordering and consistent relationship by
ONJ stage. There was minimal subject distress.
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OBJECTIVE: To compare the valuation of ovarian cancer health
states as assessed by the visual analog scale (VAS) and the stan-
dard gamble (SG). METHODS: Ovarian cancer patients and
oncologists were enrolled in this study. Participants were asked to
score six hypothetical treatment scenarios using the VAS and SG.
Values were compared using the intraclass correlation coefﬁcient
(ICC) and t-test. RESULTS: Fifty-one patients and 34 oncologists
were enrolled to this study. Participants were asked to rank order
health states in a one-time interview using the VAS, followed by
assessment of the health states, in random order, using the SG.
This resulted in 244 and 199 SG-VAS data pairs for analysis from
patients and oncologists, respectively. The ICC among patients
was 0.003 (95% CI: -0.122 to 0.129; F-test, p = 0.479). A
signiﬁcant difference was observed between VAS and SG scores
for patients receiving chemotherapy (mean difference, -0.114,
p < 0.0001), but not for patients under surveillance (mean dif-
ference 0.06, p = 0.13). The SG produced higher valuation than
the VAS among patients receiving chemotherapy, but the VAS
produced higher values than the SG among patients under sur-
veillance. For oncologists, the ICC was 0.323 (95% CI: 0.192 to
0.442; F test p < 0.0001), with the SG 0.09 higher than VAS
values (p < 0.0001). Each patient group valued the health states
in the mean range of 0.46–0.61 on the VAS; however, SG utilities
ranged from 0.53–0.61 for patients receiving chemotherapy and
from 0.30–0.37 for patients under surveillance. The range of
mean values by oncologists was 0.27–0.66 and 0.30–0.70 for the
VAS and SG, respectively. CONCLUSION: There appear to be
different utility values obtained using the SG and VAS among
patients undergoing treatment, patients under surveillance, and
oncologists. This comparison suggests the importance of consid-
ering differences between these groups and method used when
conducting utility valuation research in ovarian cancer.
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OBJECTIVE: Patients with breast and colorectal cancer can use
oral and injectable chemotherapy treatments. The objective of
this study is to assess the satisfaction in patients using capecit-
abine (oral chemotherapy) in comparison with their previous
experiences with injectable chemotherapies. Also, we aimed to
compare the preference of patients on this oral drug to the
injectable chemotherapy treatments. METHODS: Quantitative
study performed with 150 oncology patients with breast and
colorectal cancer (from all Brazilian regions) who use capecitab-
ine as a treatment. A structured questionnaire with 10 answers
assessing six attributes was used. RESULTS: The average age of
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